Ambrx Biopharma American Executives
Ambrx Biopharma employs about 87 people. The company is managed by 18 executives with a total tenure of roughly 47 years, averaging almost 2.0 years of service per executive, having 4.83 employees per reported executive. Analysis of Ambrx Biopharma's management performance can provide insight into the firm performance.
Ambrx |
Ambrx Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1862) % which means that it has lost $0.1862 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3723) %, meaning that it created substantial loss on money invested by shareholders. Ambrx Biopharma's management efficiency ratios could be used to measure how well Ambrx Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Ambrx Biopharma Workforce Comparison
Ambrx Biopharma American is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 693. Ambrx Biopharma retains roughly 87.0 in number of employees claiming about 13% of equities under Health Care industry.
Ambrx Biopharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ambrx Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ambrx Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ambrx Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aromando Andrew over a year ago Acquisition by Aromando Andrew of 100000 shares of Ambrx Biopharma subject to Rule 16b-3 | ||
Sonja Nelson over a year ago Sale by Sonja Nelson of 12778 shares of Ambrx Biopharma | ||
Cormorant Asset Management Lp over a year ago Purchase by Cormorant Asset Management Lp of 1307311 shares of Ambrx Biopharma | ||
Cormorant Asset Management Lp over a year ago Purchase by Cormorant Asset Management Lp of 1401505 shares of Ambrx Biopharma | ||
Dalesandro Margaret over a year ago Acquisition by Dalesandro Margaret of 125000 shares of Ambrx Biopharma subject to Rule 16b-3 | ||
Aromando Andrew over a year ago Acquisition by Aromando Andrew of 389000 shares of Ambrx Biopharma subject to Rule 16b-3 | ||
Xiaowei Chang over a year ago Acquisition by Xiaowei Chang of 85000 shares of Ambrx Biopharma subject to Rule 16b-3 | ||
Glover Stephen C over a year ago Acquisition by Glover Stephen C of 210000 shares of Ambrx Biopharma subject to Rule 16b-3 |
Ambrx Biopharma Notable Stakeholders
An Ambrx Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ambrx Biopharma often face trade-offs trying to please all of them. Ambrx Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ambrx Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel JD | President CEO | Profile | |
| Feng Tian | Chairman of the Board, President, Chief Executive Officer | Profile | |
| Sonja Nelson | Chief Financial Officer | Profile | |
| Jared Kelly | General VP | Profile | |
| Xiao Le | Director | Profile | |
| Robert Azzara | Vice Capital | Profile | |
| Xiaowei Chang | Director | Profile | |
| Katrin Rupalla | Independent Director | Profile | |
| Joy Yan | Chief Medical Officer | Profile | |
| Shawn Zhang | Chief Officer | Profile | |
| Olivia Ware | Independent Director | Profile | |
| Ying Buechler | Chief Officer | Profile | |
| Sonja CPA | Chief Officer | Profile | |
| Andrew Aromando | Chief Officer | Profile | |
| Simon Allen | Chief Business Officer | Profile | |
| Renu MSc | Chief Officer | Profile | |
| Chris Nolet | Independent Director | Profile | |
| Sandra Aung | Chief Officer | Profile |
Ambrx Biopharma Workforce Analysis
Traditionally, organizations such as Ambrx Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ambrx Biopharma within its industry.Ambrx Biopharma Manpower Efficiency
Return on Ambrx Biopharma Manpower
| Revenue Per Employee | 47K | |
| Revenue Per Executive | 227.4K | |
| Net Loss Per Employee | 770.8K | |
| Net Loss Per Executive | 3.7M | |
| Working Capital Per Employee | 849.7K | |
| Working Capital Per Executive | 4.1M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |